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Abstract 
Background: Cytokine-induced killer (CIK) cells are a very promising cell population raising growing interest in the 
field of cellular antitumor therapy. The aim of our study was to validate the most advantageous expansion method 
for this advanced therapy medicinal product (ATMP) and to translate it from preclinical field to good manufacturing 
practices (GMP). GMP ensures that ATMP are consistently produced and controlled to the quality standards required 
to their intended use. For this reason, the use of the xenogenic sera tended to be minimized by GMP for their high 
variability and the associated risk of transmitting infectious agents.
Results: We decided to replace Fetal Bovine Serum (FBS), largely used as medium supplement for CIKs expansion, 
with other culture media. Firstly, Human Serum (HS) and Human Pool Plasma (HPP) were tested as medium supple-
ments giving not compliant results to acceptance criteria, established for CIKs, probably for the great batch to batch 
variability. Consequently, we decided to test three different serum free expansion media: X-VIVO 15, (largely used by 
other groups) and Tex Macs and Cell Genix GMP SCGM: two GMP manufactured media. We performed a validation 
consisting in three run-sand even if the small number of experiments didn’t permit us to obtained statistical results 
we demonstrated that both X-VIVO 15 and Tex Macs fulfilled the quality standards in terms of cellular growth, viability 
and identity while Cell Genix GMP SCGM resulted not compliant as it caused some technical problems such as high 
mortality.
Conclusion: In conclusion, these preclinical validation data lay the bases for a GMP-compliant process to improve 
the CIKs expansion method.
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Background
Cytokine-induced killer (CIK) cells are a very promis-
ing cell population which raise growing interest in the 
field of cellular antitumor therapy mainly due to their 
easy expansion method.
The clinical translation of adoptive immunotherapy 
with CIK cells as treatment for patients with solid 
tumors is currently the object of clinical trials and their 
number has increased in recent years [1]. They can be 
classically expanded starting from peripheral blood 
mononuclear cells (PBMCs) [2, 3] but may also be gen-
erated from bone marrow (BM) or umbilical cord blood 
precursors [4]. Sangiolo et  al. performed preliminary 
study in which CIKs were expanded in RPMI + 10% 
Fetal Bovine Serum (FBS) to evaluate their effectiveness 
for antitumor activity against autologous bone sarco-
mas [5]. CIK cells with CD3+CD56+ immunopheno-
type have cytotoxic effects similar to those previously 
obtained by other groups [3, 6, 7], as they efficiently 
killed sarcoma cells. Therefore, regulatory guidelines 
for Good Manufacturing Practices (GMP) production, 
aimed to minimize FBS, used in most ex vivo expansion 
protocols as medium supplement. This is due to the 
xenogenic sera high batch-to-batch variability and to 
the associated risk of transmitting infectious agents [8].
On these bases, our aim was translating the expan-
sion method from preclinical to GMP field. As reported 
in Directive 1394/2007, in which “the principles and 
guidelines of GMP in respect of medicinal products for 
human use and investigational medicinal products for 
human use” are defined, the safest and the most advan-
tageous CIKs expansion method that will be validated 
[9, 10]. GMP ensures that ATMP are consistently pro-
duced and controlled to the quality standards required 
to their intended use, from the collection and manipu-
lation of raw materials to the processing of intermedi-
ate products, quality controls, storage, labelling and 
packaging, and release [11]. Moreover, according to 
GMP guidelines imposing to provide acceptance crite-
ria for each pharmaceutical ATMP, and on the bases of 
our preclinical data, we have established that CIKs were 
compliant when viability was > 80%, CD3+ > 80% ± 10%, 
CD3+CD56+ ≥ 15% [5, 7].
Methods
Aim, study design and setting of the study
The aim of the study was to validate a GMP method 
for CIKs production as ATMP for treatment of human 
sarcomas. In order to replace FBS, commonly used for 
CIKs expansion, we decided to test Human Serum (HS) 
and Human Pool Plasma (HPP) as supplement medium. 
FBS was used as a control condition as our preclinical 
data were obtained culturing CIKs with RPMI + 10% 
FBS [5].
Each expansion run started from peripheral blood (PB) 
and ended with the evaluation of cellular viability, growth 
in terms of fold increase, identity and cytotoxicity.
As GMP guidelines recommend, blood has to be kept 
in quarantine in a blood bank refrigerator until the 
results of virology and sterility tests are provided. We first 
tested PB stability at 24 and 48 h from donor’s harvesting. 
From the comparative study, we observed no differences 
in terms of viability, cellular growth and identity between 
CIKs that expanded from fresh PB and those processed at 
24 and 48 h from collection (data not shown). We could 
therefore exert that PB is stable up to 48 h from harvest-
ing and this allows to wait for the virologic test results 
before starting the expansion process.
HS is a commercial serum while HPP is produced by 
the Center for Production and Validation of Hemocom-
ponents (C.P.V.H.), City of Health and Science Hospital 
of Turin. From literature emerged that HPP was already 
used instead of FBS or HS for CIKs GMP compliant 
expansion and that the presence of fibrinogen in HPP did 
not interfere with the lymphocyte expansion [12].
HPP was also subjected to Pathogen Inactivation (PI) 
technique by riboflavin (45–85 μM) and UV light (265–
370  nm). Riboflavin, commonly used to treat platelets 
or plasma (MIRASOL™ Pathogen Reduction Technol-
ogy System, Caridian BCT Biotechnologies, Lakewood, 
Colorado, USA), is a naturally occurring vitamin (vitamin 
B2) used as a photosensitizer in combination with light. 
It provides energy to inactivate living micro-organisms 
[13]. This process could guarantee the safety of cul-
ture medium for CIKs expansion in a GMP setting as it 
might obviate virus transmission problems [14]. In order 
to reduce donor specific batches variability, HPP was 
obtained through centrifugation of whole blood of mul-
tiple donors and contains a variety of valuable organic 
and inorganic elements. For these reasons, HPP seemed a 
good alternative to FBS for CIKs expansion.
Unfortunately, we obtained contradictory results (data 
not shown). We demonstrated that HS was not suitable 
for our aim as it drastically compromised the quality of 
CIKs expansion in terms of cellular viability, growth and 
identity. On the contrary, the RPMI + 10% HPP expanded 
CIKs had grown up more than those in HS with a fold 
increase similar to those of RPMI + 10% FBS expanded 
CIKs. However, this trend was not maintained in the fol-
lowing expansion runs and the immunophenotype was 
not always compliant to the acceptance criteria demon-
strating the presence of a great variability between HPP 
batches. This was a bad characteristic which compro-
mised the choice of this supplement for the CIKs expan-
sions. Moreover, the need to freeze and thaw HPP for its 
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storage could bring to radical oxygen species formation 
[15] which are toxic causing the cells viability and growth 
decrement.
For all these reasons we tried to find an alterna-
tive expansion medium less variable but as efficient as 
RPMI + 10% FBS. We decided to test three different 
serum free expansion media: X-VIVO 15, largely used 
by other groups [16] and two GMP manufactured media: 
Tex Macs and Cell Genix GMP SCGM. Viability, cellular 
growth in terms of fold increase, immunophenotype and 
cytotoxicity were evaluated and compared at the end of 
each expansion run.
Peripheral blood collection and PBMCs isolation
The Center for Production and Validation of Hemocom-
ponents (C.P.V.H.) of the City of Health and Science Hos-
pital of Turin provided the whole Peripheral blood from 
healthy donors. For ethical reasons, we received, after 
informed consent, only the PB which were not conform 
for donation purposes and so considered a waste mate-
rial to be eliminated (examples: donations interrupted for 
technical problems in the collection with a volume lower 
than the reference values for the acceptance of transfu-
sion material).
The raw material was collected and validated by 
C.P.V.H., which verified the compliance of all virology 
tests carried out on the collected PB. Blood was stored 
in the blood bank refrigerator (+ 4 °C) and kept in quar-
antine until the results of virology tests were provided. 
After about 24 h from collection, the PB was processed 
for CIKs production. The study design is illustrated in 
Fig. 1.
PBMCs were separated by density gradient centrifuga-
tion using HISTOPAQUE-1077 (Sigma-Aldrich St. Louis, 
US) and subjected to washing cycles in Phosphate buff-
ered saline (PBS) (EuroClone, Pero, MI, Italy) and finally 
re-suspended in the culture medium at the cellular con-
centration of 2 × 106 cells/ml.
CIKs expansion
We compared three different serum-free culture media 
in order to obtain the best expansion condition: X-VIVO 
15 (Lonza, Allendale, NJ, US), largely used in the clinical 
grade lymphocytes expansion [16] and other two culture 
media generated in GMP conditions: Cell Genix GMP 
SCGM (CellGenix, Freiburg, Germany) and Tex Macs 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, 
30 × 106 of cells were seeded in 15 ml of culture medium. 
We cultured the CIKs in T75 flasks (Corning Incorpo-
rated, NY, USA). They were not a treated plastic type and 
they were endowed of vented cap. They were maintained 
in a vertical position in order to ensure a better oxy-
genation of cellular suspension, to reduce the culturing 
medium distribution surface and to have an appropriate 
culturing medium volume in order to re-suspend homo-
geneously the cells.
At Day 0, 1000  U/ml IFN-γ was added (Boehringer 
Ingelheim, Vienna, Austria). At Day 1, 50  ng/ml CD3 
Pure, which is IgG anti-CD3 (OKT-3) (170-076-124, 
Miltenyi Biotec, Bergisch Gladbach, Germany), and 
300 IU/ml of Proleukin which is IL-2 cytokines (Novartis, 
Origgio, VA, Italy) were added [4]. Fresh medium and 
Proleukin (300 U/ml) were added weekly (every 3  days) 
during culture, and the cell concentration was main-
tained at 1-1.5 × 106 cells [17]. The fold increase of CIKs 
was calculated as follow: (%CD3+ × total cells counted at 
Day 20–21)/(%CD3+ × seeded cells at Day 0).
After 20–21  days, CIK cells culture was stopped and 
the quality controls were performed (cell count and via-
bility, immunophenotype and sterility).
Cell count and viability evaluation
CIK cells were counted at optical microscope, using 
Burker chamber as indicated in the European Pharmaco-
poeia (Chapter 2.7.29) [18]. The best counting condition 
in order to obtain a measurement as reliable as possible 
was between 80 and 150 cells in 25 squares of Burker 
chamber. The cellular viability was evaluated with Trypan 
Blue Method (Sigma-Aldrich, St. Louis, US) [18].
Flow cytometry
Flow cytometry was performed according to European 
Pharmacopoeia (Chapter  2.7.24) using Beckman Coul-
ter NAVIOS (Beckman Coulter, Brea, CA, US) [19]. At 
Day 0, before PBMCs seeding, basal flow cytometry was 
performed in order to evaluate the lymphocyte sub-
populations. About 0.5–1 × 106 cells were incubated for 
20 min, at 4 °C in the dark with respectively CYTO-STAT 
TetraCHROME CD45-FITC, CD56-RD1, CD19 ECD, 
CD3-PC5 (Beckman Coulter, Brea, CA, US) for B lym-
phocytes and CYTO-STAT TetraCHROME CD45-FITC, 
CD4-RD1, CD8-ECD, CD3-PC5 (Beckman Coulter, Brea, 
CA, US) for T lymphocytes. Cells were washed and re-
suspended in 300 µl of PBS. After 20–21 days of expan-
sion flow cytometry was performed to evaluate the CIKs 
identity. Briefly, 0.5–1 × 106 cells were incubated as pre-
viously described with CD3-FITC, CD56-PE, CD45 KO 
(Beckman Coulter, Brea, CA, US). As negative control, 
0.5–1 × 106 cells were incubated without antibody. For 
data analysis, we designed the physical gate as [A]. From 
this gate, we obtained the CD3+ and the CD56+ cell 
population. In the dot plot CD3xCD56 we gated the CIK 
double positive CD3+CD56+ cell population. The tail is 
representative of the primitive CD3+CD56+. These cells 
were the cellular therapy product as it was in compliance 
with the identity acceptance criteria.
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Fig. 1 Methodological flow chart. Graphical Illustration of the experimental steps of CIKs expansion method in the three culturing conditions: 
X-VIVO 15, Tex Macs and Cell Genix GMP SCGM
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CIKs cytotoxicity
CIKs tumor-killing ability was assessed against target 
primary tumor cells obtained from surgical biopsies of 
gastro-intestinal stromal tumor (GIST).
CIK cells were co-cultured at progressively decreas-
ing effector:target (E:T) ratios, 40:1, 20:1, 10:1, 5:1, 
2.5:1, 1:1, 1:2, and 1:4 for 72 h in 200 μl of medium with 
Proleukin at a concentration of 300 U/ml at 37  °C 5% 
 CO2. A confirmatory method was tested in parallel to 
determine the number of viable, metabolically active, 
target cells in culture, based on the quantification of 
ATP present (CellTiter-Glo Luminescent Cell Viability 
Assay, Promega Italia s.r.l.). Tumor cells, in the absence 
of CIK cells, were used as a control to assess spontane-
ous mortality. The percentage of tumor-specific lysis for 
each E:T ratio was calculated as experimental − sponta-
neous mortality/100 − spontaneous mortality × 100 [5].
Sterility
Sterility test was performed on cellular supernatants 
at the end of CIKs expansion. Briefly, 10  ml and 4  ml 
of supernatant respectively for anaerobic and aerobic 
microorganisms and fungal/yeasts species, were inocu-
lated within the Bact-ALERT® FN and Bact-ALERT® 
PF (Biomérieux, INC. Durham, NC). The sample 
was then analyzed by the Laboratory of Bacteriology 
and Virology—Pediatric Clinical Pathology of City of 
Health and Science of Turin. The results were available 
after 7–8 days of incubation.
Statistical analysis
Cell growth, viability, immunophenotype and cytotox-
icity assay data were analyzed with the GraphPad pro-
gram (version Prism 5). The data were expressed as 
mean ± standard deviation. The statistical tests were 
chosen on the basis of the number of samples and the 
distribution of the data. The latter was evaluated by 
Shapiro–Wilk Test, which is considered the best for the 
normality evaluation for a small number of samples. 
Paired T test was performed when the distribution was 
normal, on the contrary, when there was not a Gauss-
ian distribution, Wilcoxon Rank Test was used. Finally, 
Bonferroni’s multiple comparison Test was conducted 
to compare the mean values on each data row, which 
represent a condition, with the control mean data row.
Results
Comparison between culture expansion media
We compared X-VIVO 15 with other two serum-free 
culture media: Cell Genix GMP SCGM and Tex Macs, 
both manufactured in GMP conditions.
Three validation runs were performed and viability, 
cellular growth, identity and cytotoxicity were evalu-
ated at Day 20–21 of CIKs expansion and compared in 
the three culture conditions.
Viability data of each culture condition were analyzed 
by the Paired T-test that did not highlight any statistical 
differences between studied groups. Nevertheless, the 
CIKs viability recorded at Day 21 of expansion in Cell 
Genix GMP SCGM was not compliant in two of the three 
runs (viability < 80%) (data not shown). The results are 
shown in Fig. 2.
Cellular growth was expressed as fold increase of 
CD3+ from Day 0 to Day 20–21. As shown in Fig. 3, CIKs 
expanded in Cell Genix GMP SCGM, grew less than both 
X-VIVO 15 and Tex Macs (X-VIVO 15: 47.11 ± 31.79; 
Tex Macs: 34.44 ± 6.42; Cell Genix GMP SCGM: 
9.17 ± 10.80).
We observed some differences in the CIKs morphol-
ogy during the expansion between the three tested condi-
tions. In particular, CIKs expanded in Cell Genix GMP 
SCGM formed numerous aggregates, which were differ-
ent from the classic clusters observed in X-VIVO 15 and 
Tex Macs cultures. These aggregates caused many diffi-
culties in cell count procedures it resulted impossible to 
establish cells concentration (N° cells/ml) and viability. 
The abnormal agglomerates in fact were not broken by 
resuspension and were all positive to trypan blue stain-
ing. As shown in Fig.  4, the aggregates of Cell Genix 
GMP SCGM were dark and had irregular edges. In both 
X-VIVO 15 and Tex Max the clusters were circular and 
light reflective indicating the viability of the agglomerates 
forming cells.
Moreover, the X-VIVO 15 and Tex Macs conditions had 
higher CD3+ levels than those found in the Cell Genix 
Fig. 2 Viability study between X-VIVO 15, Tex Macs and Cell Genix 
GMP SCGM. All data were analyzed with the Paired-T statistical Test 
and represented as mean ± St.Dev (N = 3)
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GMP SCGM condition. (X-VIVO 15: 97.56 ± 1.15; Tex 
Macs: 97.84 ± 1.27; Cell Genix GMP SCGM: 79.85 ± 1.94) 
(Fig.  5a). The Cell Genix GMP SCGM condition was 
not compliant to the release criteria in term of CD3+ % 
in one of the three validation runs (CD3+ % = 77.62). 
Similarly, the percentage of CD3+56+ cells was higher 
in the X-VIVO 15 and Tex Macs conditions compared 
to the Cell Genix one. Although the percentage of 
CD3+56+ was higher in X-VIVO 15 than in Tex Macs, 
there were no statistically differences (X-VIVO 15: 
41.91 ± 16.76; Tex Macs: 35.76 ± 11.16; Cell Genix GMP 
SCGM: 34.36 ± 10.18) (Fig. 5b).
Finally, Cell Genix GMP SCGM CIKs showed a sta-
tistically higher cytotoxic action than both X-VIVO 
15 and Tex Macs CIKs. (i.e. E/T ratio 1:1 → X-VIVO 
15: 55 ± 11.61; Tex Macs: 42 ± 14.86; Cell Genix GMP 
SCGM: 82 ± 17.47). The difference is statistically 
Fig. 3 Statistical analysis of cellular growth expressed as fold 
increase. Data were analyzed with the Paired-T statistical Test and 
represented as mean ± St.Dev (N = 3)
Fig. 4 Representative Morphological image of CIKs’ clusters/aggregates in the three culturing conditions: X-VIVO 15 (a), Tex Macs (b) and Cell Genix 
GMP SCGM (c). The analysis was performed at optic microscope 20X magnification
Fig. 5 Percentage of CD3+ (a) and CD3+CD56+ (b) in the three studied conditions. Data were analyzed with the Paired-T statistical Test and 
represented as mean ± St.Dev (N = 3)
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significant (p < 0.01) also between X-VIVO 15 vs Tex 
Macs (Fig. 6).
Sterility
Sterility test was performed at the end of each validation 
run of expansion. All the runs resulted compliant, as bac-
teriology report was always negative for the presence of 
Gram + and Gram- Bacteria, Fungal/yeasts.
Discussion
CIK cells are a heterogeneous subset of polyclonal T 
cells with the phenotype CD3+CD56+ and functional 
properties of NK cells. They rise from CD3+ T cell pre-
cursors and during the expansion acquire the expression 
of CD56+. Furthermore, CIK cells CD3+CD56+ are 
endowed with a potent MHC-unrestricted cytotoxicity 
against tumor target. Their antitumor activity is due to 
their cytotoxic action mediated by the perforins and by 
the interaction Fas–Fas ligand [2]. They were firstly clini-
cally tested against onco-haematology malignancies [4, 
16] and then against solid tumors [5, 7]. For this reason, 
they have emerged as important ATMP for the therapy 
of a lot of malignancies such sarcomas [5]. Their devel-
opment has to follow a specific regulatory framework 
which is applied to traditional pharmaceutical drugs. 
On these basis, CIKs production is governed in Europe 
by the Directive 2001/83/EC, amended by Regulation 
1394/2007 [9, 10].
Our aim was to extend the CIKs expansion method 
from preclinical field to GMP. We replaced FBS, in 
accordance to GMP guidelines that limit the xenogenic 
serum for human use. We tried to use as supplement 
medium HS and HPP but the obtained results demon-
strated a great variability in HPP batches. On the other 
hand, HS was not a good alternative to FBS.
For these reasons we decided to test serum free 
medium by comparing X-VIVO 15, commonly used 
in CIKs expansion [4], Tex Macs and Cell Genix GMP 
SCGM, both produced in GMP conditions.
The results were not significantly different as the 
number of experiments was too low and there was a 
great variability due to the raw CIKs cultures started 
materials. In this validation in fact, three runs were suf-
ficient to underline methodological criticisms and to 
identify the best culturing condition, but not to obtain 
statistically differences. Both X-VIVO 15 and Tex Macs 
proved to be valid for CIKs expansion in terms of cell 
growth, viability and cell identity. In fact, as previously 
described X-VIVO 15 and Tex Macs expanded CIKs 
were more satisfactory in terms of cellular viability and 
identity than those expanded with Cell Genix (Figs.  2, 
3, 5). Moreover, Cell Genix GMP SCGM could promote 
aggregates formation which caused several technical 
problems in terms of cellular resuspension during cell 
count (Fig.  4). The microscopic observation led us to 
demonstrate that they were not active CIKs clusters but 
dead cells aggregates as they were positive to trypan 
blue staining. This was a very critical aspect as it com-
promised the cellular viability and growth evaluation. 
An accurate cell count represents a crucial point for a 
correct concentration cell seeding (1–1.5 × 106/ml). 
The CIKs potency against tumor cells was measured by 
citotoxicity test: in general CIKs cells recognize tumor 
targets and kill them without prior exposure or prim-
ing. The NKG2D molecule expressed on the membrane 
of CIK plays a pivotal role in their mechanism of action 
as it recognizes and interacts with stress inducible mol-
ecules MHC-unrestricted expressed only by tumor cells 
[17].
By CIKs cytotoxicity test emerged that Cell Genix 
GMP SCGM was the most cytotoxic condition, statis-
tically different from the other two. Then, X-VIVO 15 
cytotoxicity was statistically higher than Macs (Fig. 6). As 
Cell Genix GMP SCGM is a culture medium specific for 
NK expansion it was able to expand a significant amount 
of CD3−CD56+ cells if compared to X-VIVO 15 and Tex 
Macs, (Fig. 7c). This confirmed that a higher amount of 
NK cells make cellular suspension more cytotoxic [20]. 
This phenomenon has already been observed in CIKs 
expanded with RPMI + 10% HPP (data not shown). This 
would explain also the least CD3+ amount in Cell Genix 
GMP SCGM (Fig. 7c) compared to X-VIVO 15 and Tex 
Macs cultures (Fig. 7a, b).
Fig. 6 Graphic representation of the percentages of death cells 
(Target) at each E/T ratios. The comparison was between X-VIVO 
15 vs Tex Macs vs Cell Genix GMP SCGM. Data were expressed as 
mean ± St. Deviation. The statistic test performed was Two Way 
RM ANOVA with Bonferroni Post Test; (N = 3); *p < 0.05. **p < 0.01, 
***p < 0.001
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Greater cytotoxicity certainly was a good measure 
of ATMP effectiveness against the tumor cell targets. 
Anyway, as GMP CIKs expansion was our main pur-
pose, we could not neglect that Cell Genix was not a 
good medium. In fact, two of three validation runs were 
not compliant to release criteria in terms of viability 
(> 80%) and CD3+ expression (> 80%)and the presence 
of dead cells clusters, could negatively affect the entire 
expansion process and the ATMP quality. On the other 
hand, both X-VIVO 15 and Tex Macs were valid candi-
dates for CIKs expansion.
Conclusion
As our aim is to produce CIKs with the best GMP 
expansion method in Regina Margherita Children Hos-
pital, City of health and Science of Turin Cell Factory, 
we tested the effectiveness of a commercial medium 
(X-VIVO 15) which is equivalent and less expensive 
Fig. 7 Representative of CIKs immunophenotype. The comparison was between X-VIVO 15 (a) vs Tex Macs (b) vs Cell Genix GMP SCGM (c)
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than other ones produced in GMP conditions (Tex 
Macs and Cell Genix GMP SCGM). This preclinical 
validation lays the bases for a GMP-compliant CIKs 
expansion process.
This ATMP will be used in an autologous setting in 
patients affected by refractory and unresectable soft and 
bone sarcomas and will be administered by intravenous 
infusion. For this aim a phase I clinical Trial entitled “A 
phase I study of adoptive immunotherapy with cytokine-
induced killer (CIK) cells in relapsed and non-resectable 
sarcomas after multimodal treatment” is now in the sub-
mission phase.
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